Daiichi Sankyo has claimed approval in Japan, its home market, for TROP2-targeting antibody-drug conjugate (ADC) datopotamab ...

Those key challenges impacting the care of respiratory diseases include delays in diagnosis due to the intermittent nature of ...

Opdivo Qvantig (nivolumab and hyaluronidase) has been approved for use across almost all of Opdivo's lengthy list of ...

The transaction – announced on Christmas Eve – comes after WuXi AppTec has been thrust into the US political spotlight as a ...

Embedded heuristics and decision-making: In pharma, many decisions are guided by both data and heuristics (i.e., rules of ...

Preliminary results from TROPION-Lung05 reported at the main ESMO congress last year revealed an overall response rate (ORR) ...

Looking ahead, the momentum gained in 2024 must be maintained and amplified. By fostering a culture of belonging in the ...

The Pharmaceutical Research and Manufacturers of America (PhRMA) trade body is donating $1 million to fund President-elect ...

The task ahead of Vertex now is to migrate patients already on Trikafta to the new drug. That is supported by data from the ...

At ASCO, the stellar PFS data sparked speculation that Tagrisso will become the standard of care in this type of early lung ...

In connection with the start of the phase 3 trials of PCV21, Sanofi has expanded its alliance with South Korea-based SK Bio, ...

The 2024 American College of Rheumatology (ACR) annual meeting spotlighted transformative advancements in cell therapies for ...